ONCAlert | Upfront Therapy for mRCC
Conference  >  CFS 2019   >  

Factors Affecting Second-Line Therapy Choices in HCC

Wasif M. Saif, MD
Published Online: 10:24 PM, Fri November 8, 2019


Wasif M. Saif, MD, deputy physician in chief at Northwell Health Cancer Institute and a professor at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, discusses available novel therapies for treating hepatocelluclar carcinoma (HCC) in the second-line setting.

HCC is a heterogenous disease and difficult to treat, according to Saif, but there are now multiple agents available to treat patients who have failed first-line therapy, including 3 targeted agents—regorafenib (Stivarga), cabozantinib (Cabometyx), and ramucirumab (Cyramza)—and 2 immunotherapy agents – nivolumab (Opdivo) and pembrolizumab (Keytruda). However, there are no randomized data to inform oncologists which patient is right for each agent.

Second-line treatment for HCC can be tailored based on patient characteristics, previous response to first-line therapy, and disease characteristics. Saif believes that more than 50% of patients are now able to receive second-line therapy. Immunotherapy has changed the HCC field drastically because now patients are experiencing persistent responses, concludes Saif.

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.